Novel Chemoimmunotherapy Regimen Wows in Pediatric Neuroblastoma
- OPACC
- Dec 8, 2021
- 1 min read
Adding a novel anti-GD2 antibody (hu14.18K322A) to induction chemotherapy for children with newly diagnosed high-risk neuroblastoma yielded impressive survival outcomes and improved early responses versus historical benchmarks, investigators reported.
Comments